Phone
800.277.1193
Slashed Aduhelm Prices Reflect Troubled Times for Biogen's Alzheimer's Drug
Biogen’s much-criticized pricing of its controversial Alzheimer’s drug Aduhelm took a nosedive from $56,000 to $28,200. The late December change in pricing strategy represents only the latest in multiple problems for the drug manufacturer.
Otsuka Off the Hook for Deleted Emails in Abilify Litigation
In a recent decision by a Florida federal judge, Abilify maker Otsuka Pharmaceuticals was absolved of responsibility to preserve company e-mails that might have served as evidence for plaintiffs in current Abilify litigation. The reason: the emails were written years ago, long before the company could reasonably have anticipated having to defend itself against lawsuits.
Ingestible Medical Monitors: A Slippery Slope? A Sociology Professor Raises Some Alarming Questions
Last year, Otsuka Pharmaceutical Company filed a New Drug Application with the FDA for a new form of Abilify, an anti-psychotic medication that is currently at the center of hundreds of lawsuits – and just happened to lose its patent protection in 2016.
Otsuka and Bristol-Meyer Squibb Settle Three Abilify Lawsuits; Global Settlement Agreement to Follow
Japan-based Otsuka Pharmaceuticals and its US partner, Bristol-Meyer Squibb, have settled three Abilify lawsuits that were scheduled to go to trial this summer. The plaintiffs, who suffer from gambling addiction and compulsive behavior disorders, allege that their conditions were caused by taking the antipsychotic medication Abilify (aripiprazole).
Rexulti (the Abilify Replacement) Also Causes Compulsive Gambling
Despite demonstrated dangers and side effects, which are the primary cause of action in the dozens of lawsuits currently part of a mass tort action, the atypical antipsychotic medication Abilify remains on pharmacy shelves.
There's No Clinical Proof They Help – So Why Are People With Developmental Disabilities Being Given Anti-Psychotic Medications?
A recent article in the Canadian Journal of Psychiatry highlights a disturbing trend: the increasing use of antipsychotic drugs on people with developmental and intellectual disabilities such as Down's Syndrome and autism.
Bristol-Myers Squibb and Abilify: Corporate Recidivism at its Worst
If “three strikes” laws applied to corporate “people” as they do to natural humans, Bristol-Myers Squibb (BMS) would be spending the rest of its life behind bars. Unfortunately, as we have seen, giving corporations human “rights” doesn't mean they have human accountability.
Why Does Abilify Cause Compulsive Behaviors? Here is the Answer
Aripiprazole, sold by Bristol-Meyers Squibb under the trade name Abilify, is an atypical, or “second generation” antipsychotic medication usually prescribed for the treatment of schizophrenia, bipolar disorder and depression. Originally given the green light by the FDA in 2002, Abilify was approved for the treatment of depression in 2007.
Troy Rafferty of Levin Papantonio Selected to Team of Attorneys to Lead Abilify Litigation
Award winning personal injury attorney Troy Rafferty, a shareholder with the Levin Papantonio Law Firm, has been appointed to the leadership team handling cases related to the Abilify (Aripiprazole) Products Liability Litigation.
Abilify Compulsive Behaviors Not as “Rare” as The FDA States
In May of 2016, the FDA finally issued a warning about the antidepressant medication aripiprizole, sold under the brand name Abilify as well as in generic form. That warning stated that use of aripiprizole “may” result in compulsive, uncontrollable urges to gamble, binge eat and have sex. The agency’s warning noted that while these side effects are “rare,” they “may result in harm to the patient and others if not recognized.”